Hormonal therapy for triple negative breast cancer
Breast cancer is one of the most common cancers that affect women worldwide. Triple negative breast cancer (TNBC) is a subtype of breast cancer that accounts for only 10-20% of all breast cancer cases.
TNBC is a unique subtype of breast cancer that does not express estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). This means that the cancer growth is not driven by hormones like estrogen and progesterone, and it is not HER2-positive. As a result, TNBC is generally more aggressive and difficult to treat than other types of breast cancer.
Hormonal therapy is a type of cancer treatment that targets hormones or hormone receptors. However, hormonal therapy is not usually effective in treating TNBC because TNBC does not express hormone receptors. In other words, TNBC is hormone receptor-negative.
Despite this limitation, researchers have been exploring the use of hormonal therapy in TNBC and have made significant strides.
Aromatase inhibitors are a class of drugs that inhibit the production of estrogen in postmenopausal women by blocking the enzyme aromatase that helps convert androgens into estrogen. In premenopausal women, the ovaries are the main source of estrogen, and aromatase inhibitors are not usually effective. However, some studies have shown that aromatase inhibitors may have a role in treating TNBC.
Tamoxifen is another hormonal therapy drug that has been used in the treatment of breast cancer for over 40 years. It works by blocking the estrogen receptor. However, it is not usually effective in treating TNBC because TNBC is not estrogen receptor-positive.
Recently, researchers have discovered that TNBCs express androgen receptors. Androgens are male hormones, such as testosterone, that are also present in women. Some studies have suggested that androgen receptor-targeted therapy may be effective in treating TNBC. However, more research is needed to determine the safety and efficacy of androgen receptor-targeted therapy.
In addition to hormonal therapy, other treatment options are available for TNBC, such as chemotherapy, radiation therapy, and surgery. Chemotherapy is usually the first line of treatment for TNBC because it is more effective than other types of cancer treatment. Radiation therapy and surgery may also be used to treat TNBC.
Clinical trials are ongoing to determine the best treatment options for TNBC. Some clinical trials are exploring the use of targeted therapy drugs, such as PARP inhibitors and immunotherapy drugs, in the treatment of TNBC.
In conclusion, hormonal therapy is not usually effective in treating TNBC because TNBC is hormone receptor-negative. However, new research has shown that androgen receptor-targeted therapy may be effective in treating TNBC, and clinical trials are ongoing to determine the best treatment options for TNBC. It is important for women with TNBC to discuss their treatment options with their healthcare provider and to participate in clinical trials when possible. Treatment decisions should be made based on the individual patient's health status and personal preferences.